# Cocrystal Pharma, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Cocrystal Pharma, Inc.). ## Overview Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing antiviral therapeutics for serious and chronic viral diseases. Its programs use structure-based drug design to advance small-molecule candidates for influenza, coronavirus, norovirus, and hepatitis C, but the company does not yet have approved products or recurring product revenue. ## Products & services • Structure-based antiviral drug discovery and development • Influenza antiviral program, including CC-42344 • Norovirus and coronavirus clinical candidates, including CDI-988 • Broad-spectrum influenza A/B replication inhibitors • Preclinical and clinical-stage antiviral pipeline partnering - **Clinical-stage antiviral candidates** (70%) — Small-molecule drug candidates in preclinical and clinical development for viral diseases. - **Discovery platform and research programs** (20%) — Structure-based technologies used to identify and optimize novel antiviral compounds. - **Partnering and collaboration opportunities** (10%) — Out-licensing or strategic collaboration potential for programs after early clinical work. - Structure-based antiviral drug discovery and development - Influenza antiviral program, including CC-42344 - Norovirus and coronavirus clinical candidates, including CDI-988 - Broad-spectrum influenza A/B replication inhibitors - Preclinical and clinical-stage antiviral pipeline partnering ## Customers Cocrystal does not sell commercial products today; its economic counterparties are primarily investors, clinical research organizations, and potential pharmaceutical partners. If its programs succeed, future customers would likely be pharmaceutical licensees, distributors, and healthcare systems that adopt approved antiviral therapies. - **Equity investors** (primary) — Provide capital through public and private offerings to fund R&D and operations. - **Strategic pharmaceutical partners** (secondary) — May license or co-develop antiviral candidates after clinical de-risking. - **Clinical research organizations** (secondary) — Buy trial management and development services to execute studies efficiently. - **Future healthcare buyers** (emerging) — Hospitals, physicians, and payers would buy approved antivirals if programs reach market. - Current funding comes mainly from equity investors, not product buyers - Clinical research organizations support trial execution and data generation - Potential pharma partners may license programs after proof-of-concept - Future end users would be physicians, hospitals, and patients needing antivirals - Public health and infectious-disease markets drive demand for approved therapies ## Geography The company is headquartered in the United States and appears to run a U.S.-centric corporate and financing model, with clinical development activity that can extend into international trial sites and regulatory processes. The 10-Q references the MHRA, indicating at least some clinical or regulatory interaction in the United Kingdom, but no country-level revenue disclosure is provided because the company has no commercial sales. - United States is the corporate base and main financing market - Clinical development may involve non-U.S. trial and regulatory activity - MHRA references indicate UK regulatory interaction for study amendments - No commercial revenue geography is disclosed because products are not sold - Geographic exposure is mainly operational and regulatory, not sales-driven ## Strategy Cocrystal’s strategy is to advance a focused antiviral pipeline through early clinical proof-of-concept while preserving cash through disciplined R&D spending. The company also seeks strategic partners for programs such as CC-31244 and relies on equity financing and the ATM facility to fund development until it can create licensing or commercialization value. - **Advance lead antiviral candidates through clinical development** (short-term) — Clinical data are needed to validate efficacy, safety, and partnering value. - **Secure strategic partnerships** (medium-term) — Partnerships can provide non-dilutive funding and external development capability. - **Preserve liquidity and access capital markets** (short-term) — The company has no ongoing product revenue and depends on external financing. - Prioritize norovirus, coronavirus, and influenza programs - Use structure-based design to differentiate antiviral candidates - Seek clinical proof-of-concept to attract partners - Control spending as programs move through costly trials - Use equity financing and ATM access to fund operations - Pursue out-licensing or collaboration to monetize assets ## Risks The company faces substantial going-concern and financing risk because it has no approved products, no recurring revenue, and limited cash relative to planned R&D spending. Clinical development risk is also high: trial design, infection rates, regulatory approvals, and candidate safety can all delay or derail programs, while inflation and tariff-related cost pressure could further strain working capital. - **Going-concern and liquidity shortfall** [critical] — The company states its cash is not expected to support working capital needs for 12 months. - **Clinical trial execution risk** [high] — The influenza Phase 2a study faced low infection rates, limiting data analysis. - **Financing dilution risk** [high] — Future funding is expected to come from equity or partner transactions that may dilute holders. - **Regulatory and development delay risk** [medium] — Protocol amendments or resubmissions may be needed before additional enrollment can proceed. - **Inflation and tariff cost pressure** [medium] — Higher operating and trial costs could stress limited working capital. - No approved products means no commercial revenue to fund operations - Cash may be insufficient for the next 12 months without new financing - Clinical trials can fail due to weak efficacy, safety, or enrollment issues - Regulatory changes or protocol amendments can delay development timelines - Equity financing may be highly dilutive to existing shareholders - Inflation and tariffs could raise operating and trial costs ## Accounting As a clinical-stage biotech, Cocrystal’s reported results are driven mainly by R&D expense timing, stock-based compensation, and estimates around going-concern and liquidity. The company also notes prior warrant liabilities and uses U.S. GAAP estimates that can materially affect reported losses, cash runway assessments, and balance-sheet classification. - **Research and development expense recognition** — Drives quarterly loss volatility and reflects pipeline progress - **Going-concern assessment** — Important for liquidity analysis and valuation - **Warrant liability accounting** — Can create non-cash fair value changes in earnings - **Accounting estimates and assumptions** — Can materially affect reported expenses and balance-sheet items - R&D expense timing reflects clinical trial progress and program stage - General and administrative costs can swing with insurance and professional fees - Going-concern assessment affects disclosure and investor interpretation - Warrant liability accounting can create non-cash income or expense - Management estimates affect asset, liability, and expense measurements --- *Last updated: 2026-04-28T19:58:28.842913+00:00*